Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Results from the Phase III VERITAC-2 trial demonstrated that vepdegestrant reduced the risk of disease progression or death ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Pfizer (PFE) and Arvinas (ARVN) aim to seek FDA approval for thier breast cancer therapy vepdegestrant in H2 2025. Read more ...

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations. Arvinas on ...

Breast cancer (BC) is the most prevalent cancer among women globally with two million diagnosed cases each year. Oestrogen ...

New breast cancer drug vepdegestrant shows promising results in increasing survival rates for patients with ESR1 mutations.

H.C. Wainwright analyst Andrew Fein notes that Arvinas (ARVN) shared the final data from the VERITAC-2 trial, which the firm sees positioning ...

and NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623 ...